|
Hutchmed China Ltd on Monday said it had begun phase-three clinical trials of its lymphoma treatment in China. The Shanghai-based pharmaceutical firm is testing its drug HMPL760 in combination with rituximab, gemcitabine and oxaliplatin, or RGemOx, on patients with relapsed or refractory diffuse large B-cell lymphoma. This is ‘the most common form of aggressive non-Hodgkin lymphoma’, Hutchmed noted, ‘accounting for approximately 40% of all NHL cases in China’. The trial focuses on patients ‘who are relapsed or refractory after prior treatment with first-line systemic chemotherapy, immunotherapy, or immunochemotherapy regimens and ineligible for transplantation,’ the company added. It will assess progression-free survival, overall survival, objective response rates, complete response rates, duration of response, clinical benefit rates, time to response, safety and PK characteristics. Around 240 patients are expected to enrol in the trial, with the first dose given last Friday. Hutchmed shares fell 3.4% to 195.06 pence on Monday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
